AMA updates advocacy aims for AI in healthcare

The American Medical Association is pushing for policies around AI in healthcare that don’t penalize physicians who avoid the technology while it’s still in a state of flux on so many fronts, from regulatory oversight to clinical usefulness.

At the same time, the group is opposing mandates aimed at requiring the use of healthcare AI as a condition of licensure, participation, payment or coverage.

These were among the updated AI advocacy positions the AMA announced at its annual meeting in Chicago June 12.

“Medical experts are working to determine the clinical applications of AI—work that will guide healthcare in the future,” said Gerald Harmon, MD, former chair of the AMA’s board of trustees. “These experts, along with physicians, state and federal officials, must find the path that ends with better outcomes for patients. We have to make sure the technology does not get ahead of our humanity and creativity as physicians.”

In its official communications, the group uses AI to denote augmented rather than artificial intelligence, noting on its website that the former term “focuses on AI’s assistive role, emphasizing that its design enhances human intelligence rather than replaces it.”

The updated policy prescriptions build on the AMA’s initial recommendations for AI from their annual meeting of 2018.

Click to read the rest of the items on the AMA’s 2019 advocacy to-do list: 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup